Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 4/29/24 → 4/29/26 |
Funding
- Merck Sharp & Dohme Corporation: $21,218.00
24-GU-84-MSD (003-00):A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Next-Generation Hormonal Ag
- Myint, Zin (PI)